Point72 Asia Singapore Pte. Ltd. Purchases New Stake in Danaher Co. (NYSE:DHR)

Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Danaher Co. (NYSE:DHR) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 26,918 shares of the conglomerate’s stock, valued at approximately $7,484,000. Danaher accounts for approximately 1.4% of Point72 Asia Singapore Pte. Ltd.’s portfolio, making the stock its 11th largest position.

Several other institutional investors also recently made changes to their positions in the stock. Cetera Advisors LLC boosted its holdings in Danaher by 44.3% during the first quarter. Cetera Advisors LLC now owns 27,346 shares of the conglomerate’s stock worth $6,829,000 after buying an additional 8,389 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of Danaher by 5.3% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,366 shares of the conglomerate’s stock worth $337,000 after acquiring an additional 69 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Danaher by 51.2% in the 2nd quarter. GAMMA Investing LLC now owns 3,355 shares of the conglomerate’s stock worth $838,000 after acquiring an additional 1,136 shares during the period. HBW Advisory Services LLC acquired a new stake in shares of Danaher in the 2nd quarter worth approximately $216,000. Finally, ST Germain D J Co. Inc. increased its stake in Danaher by 6.8% in the 2nd quarter. ST Germain D J Co. Inc. now owns 3,077 shares of the conglomerate’s stock valued at $769,000 after purchasing an additional 197 shares in the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Trading Up 0.4 %

Shares of DHR opened at $239.69 on Friday. Danaher Co. has a twelve month low of $215.68 and a twelve month high of $281.70. The firm has a market capitalization of $173.12 billion, a P/E ratio of 45.74, a price-to-earnings-growth ratio of 4.41 and a beta of 0.85. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. The stock’s fifty day simple moving average is $254.59 and its 200 day simple moving average is $259.44.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The company had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same period last year, the business posted $2.02 EPS. The company’s quarterly revenue was up 3.1% compared to the same quarter last year. On average, equities research analysts forecast that Danaher Co. will post 7.5 earnings per share for the current year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were paid a dividend of $0.27 per share. The ex-dividend date of this dividend was Friday, September 27th. This represents a $1.08 annualized dividend and a yield of 0.45%. Danaher’s dividend payout ratio is currently 20.61%.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Raymond James lowered their target price on Danaher from $310.00 to $300.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Barclays decreased their price objective on Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 23rd. StockNews.com raised shares of Danaher from a “hold” rating to a “buy” rating in a research note on Wednesday. UBS Group decreased their price target on shares of Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a research note on Wednesday, October 23rd. Finally, Wells Fargo & Company assumed coverage on shares of Danaher in a research report on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 price objective for the company. Five analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and a consensus target price of $287.16.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.